CA3220957A1 - Crystalline solid forms of a bet inhibitor - Google Patents
Crystalline solid forms of a bet inhibitor Download PDFInfo
- Publication number
- CA3220957A1 CA3220957A1 CA3220957A CA3220957A CA3220957A1 CA 3220957 A1 CA3220957 A1 CA 3220957A1 CA 3220957 A CA3220957 A CA 3220957A CA 3220957 A CA3220957 A CA 3220957A CA 3220957 A1 CA3220957 A1 CA 3220957A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- reacting
- temperature
- cancer
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01M—CATCHING, TRAPPING OR SCARING OF ANIMALS; APPARATUS FOR THE DESTRUCTION OF NOXIOUS ANIMALS OR NOXIOUS PLANTS
- A01M31/00—Hunting appliances
- A01M31/06—Decoys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352220P | 2016-06-20 | 2016-06-20 | |
| US62/352,220 | 2016-06-20 | ||
| US201662397575P | 2016-09-21 | 2016-09-21 | |
| US62/397,575 | 2016-09-21 | ||
| CA3028689A CA3028689A1 (en) | 2016-06-20 | 2017-06-19 | Crystalline solid forms of a bet inhibitor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3028689A Division CA3028689A1 (en) | 2016-06-20 | 2017-06-19 | Crystalline solid forms of a bet inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3220957A1 true CA3220957A1 (en) | 2017-12-28 |
Family
ID=59258384
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3220957A Pending CA3220957A1 (en) | 2016-06-20 | 2017-06-19 | Crystalline solid forms of a bet inhibitor |
| CA3220975A Pending CA3220975A1 (en) | 2016-06-20 | 2017-06-19 | Crystalline solid forms of a bet inhibitor |
| CA3028689A Pending CA3028689A1 (en) | 2016-06-20 | 2017-06-19 | Crystalline solid forms of a bet inhibitor |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3220975A Pending CA3220975A1 (en) | 2016-06-20 | 2017-06-19 | Crystalline solid forms of a bet inhibitor |
| CA3028689A Pending CA3028689A1 (en) | 2016-06-20 | 2017-06-19 | Crystalline solid forms of a bet inhibitor |
Country Status (34)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6243003B2 (ja) | 2013-03-15 | 2017-12-06 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｂｅｔタンパク質阻害剤としての三環式複素環 |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| ES2942723T3 (es) | 2014-04-23 | 2023-06-06 | Incyte Holdings Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| RS64274B1 (sr) * | 2016-06-20 | 2023-07-31 | Incyte Corp | Kristalni čvrsti oblici bet inhibitora |
| TWI882964B (zh) * | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
| EP4138847A4 (en) * | 2020-04-24 | 2024-05-22 | Memorial Sloan Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| AU2020451061A1 (en) * | 2020-06-03 | 2022-12-15 | Incyte Corporation | Combination of ruxolitinib with INCB057643 for treatment of myeloproliferative neoplasms |
| CN112137961A (zh) * | 2020-09-30 | 2020-12-29 | 严鹏科 | 一种雷帕霉素组合物及其制备方法 |
| US20240139175A1 (en) * | 2020-12-23 | 2024-05-02 | Cascade Prodrug Inc. | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (167)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59170313A (ja) | 1983-03-14 | 1984-09-26 | Kurimoto Iron Works Ltd | スクリ−ンゲ−ト |
| JPS6085739U (ja) | 1983-11-18 | 1985-06-13 | クラリオン株式会社 | テ−プレコ−ダにおけるピンチロ−ラ装置 |
| JPS6243003U (enExample) | 1985-09-05 | 1987-03-14 | ||
| JPH0314566A (ja) | 1989-06-09 | 1991-01-23 | Sankyo Co Ltd | ベンズイミダゾール誘導体 |
| US5244912A (en) | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
| FR2710915B1 (fr) | 1993-10-04 | 1995-11-24 | Synthelabo | Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique. |
| GB9410469D0 (en) | 1994-05-25 | 1994-07-13 | Erba Farmitalia | Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation |
| FR2731708B1 (fr) | 1995-03-13 | 1997-04-30 | Synthelabo | Derives de piperidine, leur procede de preparation et leur application en therapeutique |
| FR2747678B1 (fr) | 1996-04-22 | 1998-05-22 | Synthelabo | Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique |
| US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| JP2004502650A (ja) | 2000-04-21 | 2004-01-29 | ファルマシア・アンド・アップジョン・カンパニー | 線維筋痛症候群および慢性疲労症候群を治療するための化合物 |
| CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
| FR2816619B1 (fr) | 2000-11-15 | 2003-01-31 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| US6794382B2 (en) | 2000-08-08 | 2004-09-21 | Sanofi-Synthelabo | Benzimidazole derivatives, preparation and therapeutic use thereof |
| US6919334B2 (en) | 2002-09-12 | 2005-07-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine |
| WO2004047755A2 (en) | 2002-11-22 | 2004-06-10 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
| EP1462103A1 (en) | 2003-03-25 | 2004-09-29 | Faust Pharmaceuticals | NO donors, combination products and uses as modulators of neurotransmitter release |
| EP1719761A4 (en) | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | NEW HETEROCYCLIC CONNECTION |
| WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| DE102005011058A1 (de) | 2005-03-10 | 2006-09-14 | Merck Patent Gmbh | Substituierte Tetrahydro-pyrrolo-chinolinderivate |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| EP1887008B1 (en) | 2005-05-30 | 2021-04-21 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
| CN101268077A (zh) | 2005-08-05 | 2008-09-17 | 阿斯利康(瑞典)有限公司 | 三环苯并咪唑及其作为代谢型谷氨酸受体调节剂的用途 |
| WO2009020677A2 (en) | 2007-04-27 | 2009-02-12 | University Of Rochester | Compositions and methods for inhibiting g protein signaling |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| WO2009020559A2 (en) | 2007-08-03 | 2009-02-12 | The J. David Gladstone Institutes | Agents that inhibit p-tefb interactions and methods of use thereof |
| US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| DE102008052618A1 (de) | 2008-10-21 | 2010-04-22 | Henkel Ag & Co. Kgaa | Tricyclische Aldehyde und C,H-acide Verbindungen |
| US8669249B2 (en) | 2009-03-27 | 2014-03-11 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| TW201105681A (en) | 2009-06-10 | 2011-02-16 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| TW201103941A (en) | 2009-06-10 | 2011-02-01 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| WO2011024987A1 (ja) | 2009-08-31 | 2011-03-03 | 塩野義製薬株式会社 | 芳香族縮合へテロ環誘導体およびそれらを含有する医薬組成物 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| PL2496582T3 (pl) | 2009-11-05 | 2016-08-31 | Glaxosmithkline Llc | Benzodiazepinowy inhibitor bromodomeny |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP2496945B1 (en) | 2009-11-05 | 2015-04-01 | GlaxoSmithKline LLC | Novel process |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| PT2722334E (pt) | 2009-11-05 | 2016-03-11 | Glaxosmithkline Llc | Inibidor do bromodomínio da benzodiazepina |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| MX2012012353A (es) | 2010-04-23 | 2013-02-07 | Kineta Inc | Compuestos anti-virales. |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| JP5913292B2 (ja) | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 代謝を調節する組成物および方法 |
| JP5844358B2 (ja) | 2010-06-22 | 2016-01-13 | グラクソスミスクライン エルエルシー | ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| CA2825028A1 (en) | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| CN103547152A (zh) | 2011-02-23 | 2014-01-29 | 西奈山伊坎医学院 | 溴结构域蛋白的抑制剂作为基因表达的调节剂 |
| RU2013143747A (ru) | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106799D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2723338A2 (en) | 2011-06-24 | 2014-04-30 | The Trustees of Stevens Institute of Technology | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| CA2843643A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| SG2014004162A (en) | 2011-08-31 | 2014-03-28 | Otsuka Pharma Co Ltd | Quinolone compound |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| EP2757887B1 (en) | 2011-09-22 | 2017-04-26 | VIIV Healthcare UK Limited | Pyrrolopyridinone compounds and methods for treating hiv |
| CN103857391B (zh) | 2011-09-30 | 2016-06-08 | 沈阳蓝桑医药生物技术研发有限公司 | 含有瑞利格内酯的药物组合物及其应用 |
| WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| RS58911B1 (sr) | 2011-11-01 | 2019-08-30 | Resverlogix Corp | Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20150133434A1 (en) | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| HK1206744A1 (en) | 2012-04-20 | 2016-01-15 | Abbvie Inc. | Isoindolone derivatives |
| US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| RU2632915C2 (ru) | 2012-06-12 | 2017-10-11 | Эббви Инк. | Производные пиридинона и пиридазинона |
| JP6265979B2 (ja) | 2012-06-25 | 2018-01-24 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 |
| WO2014015175A1 (en) | 2012-07-18 | 2014-01-23 | Massachusetts Institute Of Technology | Compositions and methods for modulating brd4 bioactivity |
| MX2015001880A (es) | 2012-08-16 | 2015-05-11 | Bayer Pharma AG | 2,3-benzodiacepinas. |
| EP2884983B1 (en) | 2012-08-16 | 2017-10-04 | GlaxoSmithKline LLC | Benzodiazepines for treating small cell lung cancer |
| US9663523B2 (en) | 2012-09-28 | 2017-05-30 | Bayer Pharma Aktiengesellschaft | BET protein-inhibiting 5-aryltriazoleazepines |
| HK1211209A1 (en) | 2012-09-28 | 2016-05-20 | Oncoethix Gmbh | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| AP2015008433A0 (en) | 2012-11-09 | 2015-05-31 | Jacobus Pahrmaceutical Company Inc | Heteroaryl derivatives and uses thereof |
| US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
| WO2014078257A1 (en) | 2012-11-14 | 2014-05-22 | Glaxosmithkline Llc | Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US20160193206A1 (en) | 2012-12-20 | 2016-07-07 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydropyridopyrazinones |
| CN104995190A (zh) | 2012-12-20 | 2015-10-21 | 拜耳医药股份有限公司 | Bet蛋白抑制剂二氢喹喔啉酮 |
| MX2015007921A (es) | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP2961747B1 (en) | 2013-02-27 | 2017-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| US8980879B2 (en) | 2013-03-11 | 2015-03-17 | Abbvie Inc. | Bromodomain inhibitors |
| BR112015022861A8 (pt) | 2013-03-11 | 2019-11-26 | Abbvie Inc | inibidores de bromodomínio |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| US9493411B2 (en) | 2013-03-12 | 2016-11-15 | Abbvie Inc. | Pyrrole-3-carboxamide bromodomain inhibitors |
| CN105164130A (zh) | 2013-03-12 | 2015-12-16 | 艾伯维公司 | 二氢-吡咯并吡啶酮布罗莫结构域抑制剂 |
| CN108440528A (zh) | 2013-03-12 | 2018-08-24 | 艾伯维公司 | 四环布罗莫结构域抑制剂 |
| MX369324B (es) | 2013-03-14 | 2019-11-05 | Glaxosmithkline Ip No 2 Ltd | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores de bromodominio. |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| EP2970323B1 (en) | 2013-03-14 | 2017-10-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Furopyridines as bromodomain inhibitors. |
| US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| JP6243003B2 (ja) | 2013-03-15 | 2017-12-06 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｂｅｔタンパク質阻害剤としての三環式複素環 |
| SMT201800650T1 (it) | 2013-03-15 | 2019-01-11 | Plexxikon Inc | Composti eterociclici e loro impiego |
| AU2014236606A1 (en) | 2013-03-15 | 2015-09-24 | Epigenetix, Inc. | Oxazolo(5,4-c)quinolin-2-one compounds as bromodomain inhibitors |
| EP2978757B1 (en) | 2013-03-27 | 2017-02-08 | Boehringer Ingelheim International GmbH | Indolinone analogues as brd4 inhibitors |
| WO2014154762A1 (en) | 2013-03-27 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Dihydroquinazolinone analogues as brd4 inhibitors |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| US10435364B2 (en) | 2013-04-17 | 2019-10-08 | Albert Ludwigs Universität Freiburg | Compounds for use as bromodomain inhibitors |
| WO2014173241A1 (en) | 2013-04-26 | 2014-10-30 | Beigene, Ltd. | Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| EA029312B1 (ru) | 2013-05-27 | 2018-03-30 | Новартис Аг | Производные имидазопирролидинона и их применение при лечении заболеваний |
| WO2014191911A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
| AU2014272695B2 (en) | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
| ITMI20130991A1 (it) | 2013-06-17 | 2014-12-18 | Industrie De Nora Spa | Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse. |
| JP2016521722A (ja) | 2013-06-17 | 2016-07-25 | バイエル ファーマ アクチエンゲゼルシャフト | 置換フェニル−２，３−ベンゾジアゼピン |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| US9662311B2 (en) | 2013-06-21 | 2017-05-30 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
| AR096758A1 (es) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| HK1223364A1 (zh) | 2013-06-28 | 2017-07-28 | Abbvie Inc. | 布罗莫结构域抑制剂 |
| CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| AU2014292193B2 (en) | 2013-07-16 | 2018-04-26 | Basf Se | Herbicidal azines |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| KR101672096B1 (ko) | 2013-09-30 | 2016-11-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
| HUE060767T2 (hu) | 2013-10-18 | 2023-04-28 | Celgene Quanticel Res Inc | Brómdomén inhibitorok |
| US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| CN105939996A (zh) | 2013-12-09 | 2016-09-14 | 艾伯维公司 | 用作布罗莫结构域抑制剂的二氢吡啶酮和二氢哒嗪酮衍生物 |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| CA2934788C (en) | 2014-01-09 | 2021-12-07 | Orion Corporation | Bicyclic heterocyclic derivatives as bromodomain inhibitors |
| EP3110818B1 (en) | 2014-02-28 | 2019-10-23 | The Regents of The University of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| BR112016024472B1 (pt) | 2014-04-23 | 2023-02-14 | Takeda Pharmaceutical Company Limited | Composto, medicamento, e, uso de um composto |
| US9822105B2 (en) | 2014-04-23 | 2017-11-21 | Basf Se | Diaminotriazine compounds as herbicides |
| ES2942723T3 (es) * | 2014-04-23 | 2023-06-06 | Incyte Holdings Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET |
| MX2016014299A (es) | 2014-05-02 | 2017-01-27 | Oncoethix Gmbh | Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina. |
| RU2016146099A (ru) | 2014-05-02 | 2018-06-05 | Онкоэтикс Гмбх | Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений |
| WO2015169953A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
| WO2015169951A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
| WO2015184257A2 (en) | 2014-05-30 | 2015-12-03 | Icahn School Of Medicine At Mount Sinai | Small molecule transcription modulators of bromodomains |
| RS58730B1 (sr) | 2014-06-20 | 2019-06-28 | Constellation Pharmaceuticals Inc | Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida |
| US9861077B2 (en) | 2014-07-11 | 2018-01-09 | Jaan Aked-Hurditch | Leash accessory |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| HUE050592T2 (hu) | 2014-10-24 | 2020-12-28 | Bristol Myers Squibb Co | Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként |
| MA40943A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016123709A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
| WO2016186453A1 (en) | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
| AU2016271762B2 (en) | 2015-05-29 | 2020-01-23 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity |
| CN105039258B (zh) | 2015-07-03 | 2018-04-17 | 北京大学 | 将非神经元细胞重编程为神经元样细胞的方法和组合物 |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| CN105254635A (zh) | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
| US20170127985A1 (en) | 2015-11-11 | 2017-05-11 | Medtronic Minimed, Inc. | Sensor set |
| WO2017103670A1 (en) | 2015-12-14 | 2017-06-22 | Zenith Epigenetics Lid. | 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| WO2017133681A1 (zh) | 2016-02-05 | 2017-08-10 | 正大天晴药业集团股份有限公司 | 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途 |
| RS64274B1 (sr) | 2016-06-20 | 2023-07-31 | Incyte Corp | Kristalni čvrsti oblici bet inhibitora |
| CN108069958A (zh) | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
-
2017
- 2017-06-19 RS RS20230430A patent/RS64274B1/sr unknown
- 2017-06-19 NZ NZ749956A patent/NZ749956A/en unknown
- 2017-06-19 IL IL263824A patent/IL263824B2/en unknown
- 2017-06-19 SI SI201731358T patent/SI3472157T1/sl unknown
- 2017-06-19 PE PE2018003269A patent/PE20190623A1/es unknown
- 2017-06-19 CR CR20220651A patent/CR20220651A/es unknown
- 2017-06-19 PT PT177345907T patent/PT3472157T/pt unknown
- 2017-06-19 MD MDE20190507T patent/MD3472157T2/ro unknown
- 2017-06-19 IL IL302528A patent/IL302528A/en unknown
- 2017-06-19 AU AU2017281286A patent/AU2017281286B2/en active Active
- 2017-06-19 ES ES17734590T patent/ES2945063T3/es active Active
- 2017-06-19 KR KR1020197001805A patent/KR102460046B1/ko active Active
- 2017-06-19 SG SG10201912398PA patent/SG10201912398PA/en unknown
- 2017-06-19 CA CA3220957A patent/CA3220957A1/en active Pending
- 2017-06-19 PL PL17734590.7T patent/PL3472157T3/pl unknown
- 2017-06-19 MX MX2018016281A patent/MX389145B/es unknown
- 2017-06-19 TW TW111147670A patent/TWI830533B/zh active
- 2017-06-19 CN CN201780038099.6A patent/CN109715625B/zh active Active
- 2017-06-19 WO PCT/US2017/038121 patent/WO2017222977A1/en not_active Ceased
- 2017-06-19 CN CN202111443358.8A patent/CN114366748A/zh active Pending
- 2017-06-19 TW TW106120412A patent/TWI786050B/zh active
- 2017-06-19 JP JP2018566525A patent/JP7096170B2/ja active Active
- 2017-06-19 KR KR1020227036514A patent/KR102643344B1/ko active Active
- 2017-06-19 LT LTEPPCT/US2017/038121T patent/LT3472157T/lt unknown
- 2017-06-19 PE PE2023002468A patent/PE20240236A1/es unknown
- 2017-06-19 SG SG11201811416VA patent/SG11201811416VA/en unknown
- 2017-06-19 TW TW113101597A patent/TWI854936B/zh active
- 2017-06-19 EP EP23160938.9A patent/EP4234554A3/en active Pending
- 2017-06-19 HR HRP20230466TT patent/HRP20230466T1/hr unknown
- 2017-06-19 KR KR1020257037981A patent/KR20250163425A/ko active Pending
- 2017-06-19 SM SM20230155T patent/SMT202300155T1/it unknown
- 2017-06-19 KR KR1020247006758A patent/KR102888132B1/ko active Active
- 2017-06-19 MY MYPI2023005532A patent/MY209750A/en unknown
- 2017-06-19 CA CA3220975A patent/CA3220975A1/en active Pending
- 2017-06-19 CA CA3028689A patent/CA3028689A1/en active Pending
- 2017-06-19 UA UAA201900524A patent/UA124106C2/uk unknown
- 2017-06-19 CR CR20190027A patent/CR20190027A/es unknown
- 2017-06-19 US US15/626,539 patent/US10189832B2/en active Active
- 2017-06-19 FI FIEP17734590.7T patent/FI3472157T3/fi active
- 2017-06-19 UA UAA202008134A patent/UA125476C2/uk unknown
- 2017-06-19 HU HUE17734590A patent/HUE062234T2/hu unknown
- 2017-06-19 DK DK17734590.7T patent/DK3472157T3/da active
- 2017-06-19 MY MYPI2018002677A patent/MY198892A/en unknown
- 2017-06-19 EP EP17734590.7A patent/EP3472157B1/en active Active
- 2017-06-19 PH PH1/2021/551887A patent/PH12021551887A1/en unknown
- 2017-06-19 CN CN202111446313.6A patent/CN114369091A/zh active Pending
- 2017-06-19 PH PH1/2021/551886A patent/PH12021551886A1/en unknown
-
2018
- 2018-12-07 US US16/213,202 patent/US10626114B2/en active Active
- 2018-12-19 MX MX2023009524A patent/MX2023009524A/es unknown
- 2018-12-19 CL CL2018003702A patent/CL2018003702A1/es unknown
- 2018-12-19 MX MX2021009776A patent/MX2021009776A/es unknown
- 2018-12-20 PH PH12018502709A patent/PH12018502709A1/en unknown
- 2018-12-28 CO CONC2018/0014339A patent/CO2018014339A2/es unknown
-
2019
- 2019-01-10 EC ECSENADI20191982A patent/ECSP19001982A/es unknown
-
2020
- 2020-02-19 CL CL2020000408A patent/CL2020000408A1/es unknown
- 2020-02-19 CL CL2020000407A patent/CL2020000407A1/es unknown
- 2020-03-24 US US16/828,031 patent/US11091480B2/en active Active
- 2020-12-18 US US17/127,351 patent/US11377446B2/en active Active
-
2021
- 2021-08-09 AU AU2021215112A patent/AU2021215112B2/en active Active
- 2021-08-17 IL IL285686A patent/IL285686B/en unknown
-
2022
- 2022-03-29 JP JP2022053417A patent/JP7375082B2/ja active Active
- 2022-06-02 US US17/830,494 patent/US12030882B2/en active Active
- 2022-07-01 JP JP2022107131A patent/JP7588622B2/ja active Active
-
2023
- 2023-06-15 CY CY20231100282T patent/CY1126092T1/el unknown
- 2023-09-11 AU AU2023229471A patent/AU2023229471B2/en active Active
- 2023-10-25 JP JP2023183248A patent/JP7789735B2/ja active Active
-
2024
- 2024-05-28 US US18/675,780 patent/US12459943B2/en active Active
- 2024-06-03 JP JP2024089725A patent/JP7727794B2/ja active Active
-
2025
- 2025-07-31 JP JP2025128117A patent/JP2025176008A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12459943B2 (en) | Crystalline solid forms of a BET inhibitor | |
| HK40099391A (en) | Crystalline solid forms of a bet inhibitor | |
| HK40006034B (en) | Crystalline solid forms of a bet inhibitor | |
| HK40006034A (en) | Crystalline solid forms of a bet inhibitor | |
| NZ787662A (en) | Crystalline solid forms of a bet inhibitor | |
| EA045891B1 (ru) | Кристаллические твердые формы ингибитора bet | |
| EA043645B1 (ru) | Кристаллические твердые формы ингибитора bet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231123 |
|
| EEER | Examination request |
Effective date: 20231123 |
|
| EEER | Examination request |
Effective date: 20231123 |